Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Greenberg PL et al. - In comparison with SC alone, patients receiving EPO with or without GCSF plus SC had improved erythroid responses, similar survival and incidence of AML transformation.

Related Articles

Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09    Relevance Score: 68%

Hematopoiesis-related microRNA expression in myelodysplastic syndromes
Leukemia and Lymphoma, 11/06/09    Relevance Score: 67%

Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
International Journal of Laboratory Hematology, 10/28/09    Relevance Score: 66%

Accelerated cellular senescence in myelodysplastic syndrome
Experimental Hematology, 10/22/09    Relevance Score: 66%

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09    Relevance Score: 66%

Today in Myeloproliferative Dz...keeping you current

Thrombopoietin in normal and neoplastic stem cell development
Best Practice & Research: Clinical Haematology , 12/07/09

Mechanisms of mutations in myeloproliferative neoplasms
Best Practice & Research: Clinical Haematology , 12/07/09

Solitary Plasmacytoma
American Journal of Clinical Oncology, 12/07/09